New 52 Week High Today

My Portfolio

Alkermes Plc ALKS:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD

After Hours: Last | 06/03/26 EDT

43.30

+0.54 (+1.26%)

Volume

103,727

42.76

+1.44 (+3.48%)

Volume

1,889,453

52 week range

25.17 - 42.87

Open41.32
Day High42.87
Day Low40.62
Prev Close41.32
52 Week High42.87
52 Week High Date06/03/26
52 Week Low25.17
52 Week Low Date09/08/25

Latest On Alkermes Plc

Tuesday's biggest analyst calls: Nvidia, Broadcom, Qualcomm, Booking Holdings, Blue OwlFebruary 24, 2026CNBC.com
Lightning Round: Medline is 'unbelievable', it's a buy, says Jim CramerJanuary 16, 2026CNBC.com
Cramer's Lightning Round: Sell Super Micro ComputerJanuary 16, 2026CNBC.com
Stocks making big moves midday: Goldman Sachs, AMD, Oklo, Circle InternetNovember 12, 2025CNBC.com
Stocks making the biggest moves midday: Boeing, Paccar, Intel, Mirion Tech and moreSeptember 26, 2025CNBC.com
Stocks making biggest moves midday: Block, SolarEdge, Cleveland-Cliffs and moreJuly 21, 2025CNBC.com
Tuesday's biggest analyst calls: Nvidia, Microsoft, Tesla, Broadcom, NetflixJuly 15, 2025CNBC.com

Key Stats

Market Cap7.127B
Shares Out166.68M
10 Day Average Volume2.17M
Dividend-
Dividend Yield-
Beta0.33

Latest On Alkermes Plc

Tuesday's biggest analyst calls: Nvidia, Broadcom, Qualcomm, Booking Holdings, Blue OwlFebruary 24, 2026CNBC.com
Lightning Round: Medline is 'unbelievable', it's a buy, says Jim CramerJanuary 16, 2026CNBC.com
Cramer's Lightning Round: Sell Super Micro ComputerJanuary 16, 2026CNBC.com
Stocks making big moves midday: Goldman Sachs, AMD, Oklo, Circle InternetNovember 12, 2025CNBC.com
Stocks making the biggest moves midday: Boeing, Paccar, Intel, Mirion Tech and moreSeptember 26, 2025CNBC.com
Stocks making biggest moves midday: Block, SolarEdge, Cleveland-Cliffs and moreJuly 21, 2025CNBC.com
Tuesday's biggest analyst calls: Nvidia, Microsoft, Tesla, Broadcom, NetflixJuly 15, 2025CNBC.com

KEY STATS

Open41.32
Day High42.87
Day Low40.62
Prev Close41.32
52 Week High42.87
52 Week High Date06/03/26
52 Week Low25.17
52 Week Low Date09/08/25
Market Cap7.127B
Shares Out166.68M
10 Day Average Volume2.17M
Dividend-
Dividend Yield-
Beta0.33

RATIOS/PROFITABILITY

EPS (TTM)0.90
P/E (TTM)47.55
Fwd P/E (NTM)-194.36
EBITDA (TTM)235.092M
ROE (TTM)9.36%
Revenue (TTM)1.562B
Gross Margin (TTM)86.63%
Net Margin (TTM)9.78%
Debt To Equity (MRQ)86.23%

EVENTS

Earnings Date07/27/2026(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Content From Our Affiliates

Mizuho Securities Reaffirms Their Buy Rating on Alkermes (ALKS)7 Hours AgoTipRanks
Analysts’ Top Healthcare Picks: Gilead Sciences (GILD), Alkermes (ALKS)May 26, 2026TipRanks
Alkermes Shareholders Approve Amended Stock Incentive PlanMay 20, 2026TipRanks
Alkermes’ Earnings Call Highlights Growth and LUMRYZ SurgeMay 19, 2026TipRanks
Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its PipelineMay 15, 2026TipRanks

Profile

Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other...

Richard Pops

Non-Executive Chairman of the Board

Blair Jackson

Chief Executive Officer

Joshua Reed

Chief Financial Officer, Senior Vice President

David Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

Craig Hopkinson M.D.

Executive Vice President, Research and Development and Chief Medical Officer

Address

Connaught House

1 Burlington Road, Dublin 4

Dublin

D04 C5Y6

Ireland

https://www.alkermes.com/